Actavia Life Sciences, Inc.
RASPOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$385906
P/E Ratio—
52W High$0.004
52W Low$0.0004
Actavia Life Sciences, Inc. (RASP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RASP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 20, 2024EPS Actual
-$0.00
Revenue
—
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 20, 2024
After Market Close
RASP reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2025 | Jun 23, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 30, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Feb 28, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 22, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2024 | Aug 30, 2024 | — | — | — | — | — | — |
| — Q2 FY2024 | May 20, 2024 | — | -$0.00 | — | — | — | — |
| — Q1 FY2024 | Feb 16, 2024 | — | -$0.00 | — | — | — | — |
| — Q1 FY2024 | Jan 5, 2024 | — | -$0.00 | — | — | — | — |
Q2 FY2025
Jun 23, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 30, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 28, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 22, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 30, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 20, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 16, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Jan 5, 2024
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2024 | May 20, 2024 | — | $0.02 | $0.02 | +0.00% |
| — Q1 FY2024 | Feb 16, 2024 | — | $0.01 | $0.01 | +0.00% |
| — Q1 FY2024 | Jan 5, 2024 | — | $0.01 | $0.01 | +0.00% |
| — Q3 FY2023 | Aug 14, 2023 | — | $0.02 | $0.02 | +0.00% |
| — Q2 FY2023 | May 15, 2023 | — | $0.01 | $0.01 | +0.00% |
| — Q1 FY2023 | Mar 2, 2023 | — | $0.01 | $0.01 | +0.00% |
| — Q1 FY2023 | Feb 9, 2023 | — | $0.01 | $0.01 | +0.00% |
Q2 FY2024+0.00%
Report Date
May 20, 2024
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q1 FY2024+0.00%
Report Date
Feb 16, 2024
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q1 FY2024+0.00%
Report Date
Jan 5, 2024
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q3 FY2023+0.00%
Report Date
Aug 14, 2023
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q2 FY2023+0.00%
Report Date
May 15, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q1 FY2023+0.00%
Report Date
Mar 2, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q1 FY2023+0.00%
Report Date
Feb 9, 2023
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Beat Rate0 / 7 quarters
Largest Move+0.00% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RASP ends December
Actavia Life Sciences, Inc. (RASP) most recently reported earnings on May 20, 2024 for Q2 FY2024, posting EPS of $-0.00 (in line with the analyst consensus of —). The next RASP earnings date is expected around September 1, 2026.
Each quarter, investors track RASP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RASP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RASP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RASP earnings · 4 questionsActavia Life Sciences, Inc.'s next earnings report is expected around September 1, 2026. RASP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RASP historically reports after market close (AMC).
RASP earnings datewhen is RASP earningsRASP next earnings datewhen does RASP report earningsRASP earnings calendar
▸ Source: FMP · Actavia Life Sciences, Inc. SEC filings · US GAAP · Actavia Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026